The total return over the past 12 months is -62.31% vs. +16.94% for the S&P 500. So far it's up -46.12% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (62.31%) | (42.38%) | (33.59%) | (39.91%) | N/A | N/A |
| Total Return CAGR | (62.31%) | (42.38%) | (33.59%) | (39.91%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
PharmaCyte Biotech, Inc. (PMCB)
| Year | Start price | End price | PMCB Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $0.72 | $0.39 | (46.12%) | +14.51% | (60.63%) |
| 2025 | $1.57 | $0.72 | (53.89%) | +17.72% | (71.61%) |
| 2024 | $2.16 | $1.57 | (27.31%) | +24.89% | (52.20%) |
| 2023 | $2.93 | $2.16 | (26.28%) | +26.19% | (52.47%) |
| 2022 | $2.50 | $2.93 | +17.20% | (18.17%) | +35.37% |
| 2021 | $10.39 | $2.50 | (75.94%) | +28.74% | (104.68%) |
| 2020 | $62.78 | $10.39 | (83.45%) | +18.37% | (101.82%) |
| 2019 | $57.35 | $62.78 | +9.47% | +31.22% | (21.75%) |
| 2018 | $86.49 | $57.35 | (33.69%) | (4.56%) | (29.13%) |
| 2017 | $230.79 | $86.49 | (62.52%) | +21.70% | (84.22%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
